

RECEIVED

OCT 25 2000



TECH CENTER 1600/2000  
PATENT  
0020-4491P

IN THE U.S. PATENT AND TRADEMARK OFFICE

APPLICANT(S): K. ITOH et al.  
APPLICATION NO.: 09/202,047 GROUP: 1633  
FILED: December 7, 1998 EXAMINER: L. Helms  
FOR: TUMOR ANTIGEN PROTEINS, GENES THEREFOR, AND  
TUMOR ANTIGEN PEPTIDES

**RESPONSE TO RESTRICTION REQUIREMENT**

Honorable Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

October 20, 2000

H<sub>o</sub>

K<sub>o</sub>

10-30-00

Sir:

In Response to the Restriction Requirement dated September 20, 2000, the due date for response being October 20, 2000, the following remarks are respectfully submitted.

**REMARKS**

Applicants elect Group II, claims 6-9 and 12-13 with traverse.

The Examiner alleges the subject matter of Groups I through III are not linked as to form a single general inventive concept under PCT Rule 13.1 because under PCT Rule 13.2, they lack the same or corresponding special technical features. The Examiner has indicated that the special technical feature of this case, i.e. the claimed protein, is overcome by the presence of Boon et al. (*J. Exp. Med.* 183:725-729, 1996). Applicants respectfully disagree.